Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM-PSY-003
- Development stage
- Unknown
- Lead developer
- VivaMed
- Modality
- Small Molecules
01
Overview
VM-PSY-003 is a repurposed small molecule combination therapy being developed by VivaMed for the treatment of Opioid Use Disorder (OUD). The candidate is currently in Phase 2 clinical development. By utilizing a combination of existing, repurposed small molecules, the therapy aims to address the complex neurobiological pathways involved in opioid addiction and withdrawal. While the specific constituent drugs and their exact molecular targets have not been publicly disclosed by VivaMed BioPharma, the approach leverages the established safety profiles of its components to potentially provide a more effective treatment option for OUD.
Beyond the preview
Go deeper on VM-PSY-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM-PSY-003.